Read by QxMD icon Read

Current Vascular Pharmacology

Christina Kollia, Alexios S Antonopoulos, Gerasimos Siasos, Theodosia Konsola, Evangelos Oikonomou, Nikolaos Gouliopoulos, Vasiliki Tsigkou, Aggeliki Papapanagiotou, Eva Kassi, Nicholas Tentolouris, Niki Katsiki, Manolis Vavuranakis, Athanasios G Papavassiliou, Dimitris Tousoulis
BACKGROUND: Adiponectin gene (ADIPOQ) variability may affect the risk for type 2 diabetes mellitus (T2DM) but it remains unclear whether it is involved in microvascular complications. OBJECTIVE: To explore the impact of ADIPOQ variability on markers of inflammation and angiogenesis in T2DM. METHODS: Overall, 220 consecutive T2DM patients from our outpatient diabetic clinic were genotyped for G276T (rs1501299) and T45G (rs2241766) single nucleotide polymorphisms of ADIPOQ gene...
January 7, 2018: Current Vascular Pharmacology
Jose Luis Guerrero Orriach, Marta Ramirez Aliaga
No abstract text is available yet for this article.
January 7, 2018: Current Vascular Pharmacology
Ping Song, Lan Xu, Jin Xu, Hai-Qing Zhang, Chun-Xiao Yu, Qing-Bo Guan, Meng Zhao, Xu Zhang
OBJECTIVE: To investigate the characteristics of body fat distribution and the relationship between body fat index and atherogenic index of plasma (AIP) in type 2 diabetes mellitus (T2DM) patients. METHODS: A total of 316 participants were divided into a T2DM group and a non-diabetes group (controls). According to the visceral fat area (VFA), all participants were further divided into VFA ≥100 cm2 and VFA <100 cm2 groups. To compare the differences of blood lipid, blood glucose, body fat index and AIP between the 2 groups, single factor correlation analysis was used to determine the correlation between the indexes and AIP, and multiple linear regression was used to analyse the correlation between the related factors and AIP...
January 3, 2018: Current Vascular Pharmacology
Antonis S Manolis
BACKGROUND: Intracoronary thrombus in acute myocardial infarction (MI) confers higher rates of no-reflow with attendant adverse consequences. Earlier randomized-controlled-trials (RCTs) of routine thromboaspiration during percutaneous coronary intervention (PCI) indicated a clinical benefit, but more recent RCTs were negative. However, data of selective use of this adjunctive approach remain scarce. OBJECTIVE: The aim of this single-centre prospective study was to report the results of selective thromboaspiration during PCI in patients with intracoronary thrombi, and also to provide an extensive literature review on current status of thromboaspiration...
January 1, 2018: Current Vascular Pharmacology
V Katsi, G Georgiopoulos, D Oikonomou, C Aggeli, C Grassos, D P Papadopoulos, C Thomopoulos, M Marketou, K Dimitriadis, K Toutouzas, P Nihoyannopoulos, C Tsioufis, D Tousoulis
BACKGROUND: Hypertension (HT) is an important risk factor for cardiovascular disease and might precipitate pathology of the aortic valve. OBJECTIVE: To investigate the association of HT with aortic dysfunction (including both aortic regurgitation and stenosis) and the impact of antihypertensive treatment on the natural course of underlying aortic disease. METHODS: We performed a systematic review of the literature for all relevant articles assessing the correlation between HT and phenotype of aortic disease...
January 1, 2018: Current Vascular Pharmacology
Georgios Georgiopoulos, Costas P Tsioufis, Theodoros Kalos, Nikolaos Magkas, Dimitrios Rousos, Christina Chrysohoou, Georgia Sarri, Kyriaki Syrmali, Panos Georgakopoulos, Dimitrios Tousoulis
OBJECTIVES: Accumulating evidence suggests a direct role of uric acid (UA) on left ventricular (LV) diastolic function in chronic kidney disease and heart failure (HF) patients. Recently, UA has been linked to LV hypertrophy (LVH) and diastolic dysfunction (DD) in women with preserved ejection fraction (pEF) but not in corresponding men. We sought to assess if UA could predict indices of DD in hypertensive subjects with pEF independently of gender. METHODS: We consecutively recruited 382 apparently healthy hypertensive subjects (age: 61...
December 26, 2017: Current Vascular Pharmacology
Genovefa Kolovou, Vana Kolovou, Sophie Mavrogeni
No abstract text is available yet for this article.
December 4, 2017: Current Vascular Pharmacology
Andrie G Panayiotou, Panayiotis Kouis, Andreas Kousios
No abstract text is available yet for this article.
December 4, 2017: Current Vascular Pharmacology
Stavroula A Paschou, Panagiotis Anagnostis, Andromachi Vryonidou, Dimitrios G Goulis
No abstract text is available yet for this article.
December 4, 2017: Current Vascular Pharmacology
Niki Katsiki, Konstantinos Imprialos, Charalambos Vlachopoulos
Arterial stiffness, central haemodynamics and non-alcoholic fatty liver disease (NAFLD) have been associated with increased risk for cardiovascular (CV) morbidity and mortality. Antihypertensive, antidiabetic and hypolipidaemic drugs may affect these predictors of CV risk. Such associations should be taken into consideration when treating high-risk patients.
December 4, 2017: Current Vascular Pharmacology
Vasilios G Athyros, Niki Katsiki, Michael Doumas
No abstract text is available yet for this article.
December 4, 2017: Current Vascular Pharmacology
Stella Lioudaki, Christos Verikokos, Grigorios Kouraklis, Christos Ioannou, Efi Chatziioannou, Despoina Perrea, Christos Klonaris
Paraoxonase-1 (PON-1) is a calcium-dependent enzyme that is synthesized in the liver and then secreted in blood where it is bound to high density lipoprotein(HDL). PON-1 is a hydrolase with a wide range of substrates, including lipid peroxides. It is considered responsible for many of the antiatherogenic properties of HDL. PON-1 prevents low density lipoprotein (LDL) oxidation, a process that is considered to contribute to the initiation and development of atherosclerosis. PON-1 activity and levels areinfluenced by gene polymorphisms; of the 2 common variants, one is in position 192 (Q192R) and one in position 55 (M55L)...
November 29, 2017: Current Vascular Pharmacology
M Ramirez Aliaga, J J Escalona Belmonte, Alicia Ramirez-Fernandez, M Rubio Navarro, J Cruz Manas
The implementation of cardioprotective strategies involving pre-, intra-, and postoperative interventions is key during cardiac surgery requiring extracorporeal circulation (ECC). The primary goal of this study was to review the physiopathology of and protection strategies against myocardial damage secondary to ECC during cardiac surgery. The administration of halogenated anesthetics for cardiac anesthesia is commonplace due to their well-known cardioprotective effects and their capacity to ensure hypnosis...
November 16, 2017: Current Vascular Pharmacology
Giuseppe Dattilo
Psoriasis (Pso) is a chronic inflammatory immune-mediated skin disease associated with several comorbidities. Despite the growing number of studies providing evidence for the link between Pso and cardiovascular (CV) disorders, there are still many unsolved questions, dealing with the role of the skin disease as an independent risk factor for CV events, the influence of Pso severity and duration on CV damage, the presence of psoriatic arthritis (PsA) as a predictor of increased CV mortality and morbidity and the detection of reliable clinical, laboratory and/or instrumental parameters to stratify CV risk in psoriatic patients...
November 16, 2017: Current Vascular Pharmacology
Esma Isenovic, Djodje Radak, Mihailo Neskovic, Petar Otasevic
Abdominal aortic aneurysm (AAA) is a degenerative disease of the aortic wall with potentially fatal complications. Open repair (OR) was considered the gold standard, until the emergence of endovascular aneurysm repair (EVAR), which is less invasive and equally (if not more) effective. As the popularity of endovascular procedures grows, related complications become more evident, with kidney damage being one of them. Although acute kidney injury (AKI) following EVAR is relatively common, its true incidence is still uncertain...
November 16, 2017: Current Vascular Pharmacology
Sibel Ertek
Although high density lipoprotein cholesterol (HDL-C) levels are inversely proportional to cardiovascular risk in many studies, recent pharmacological interventional studies with HDL-C raising strategies did not show a benefit in terms of vascular events. The HDL particle is heterogenous with anti-atherogenic functions and non-vascular effects. Many factors affect HDL components and may either cause compositional changes, post-translational modifications of proteins, or alter lipids and other cargo molecules; generally these factors cause more than one of these changes, resulting in functional differences...
November 16, 2017: Current Vascular Pharmacology
Susana Contreras-Duarte, Lorena Carvajal, Barbara Fuenzalida, Claudette Cantin, Luis Sobrevia, Andrea Leiva
Dyslipidaemia occurs in pregnancy to secure foetal development. The mother shows a physiological increase in plasma total cholesterol and triglycerides (TG) as pregnancy progresses (i.e. maternal physiological dyslipidaemia in pregnancy). However, in some women pregnancy-associated dyslipidaemia exceeds this physiological adaptation. The consequences of this condition on the developing foetus include endothelial dysfunction of the foetoplacental vasculature and development of foetal aortic atherosclerosis. Gestational diabetes mellitus (GDM) associates with abnormal function of the foetoplacental vasculature due to foetal hyperglycaemia and hyperinsulinaemia, and associates with development of cardiovascular disease in adulthood...
November 16, 2017: Current Vascular Pharmacology
Agata Buonacera, Benedetta Stancanelli, Lorenzo Malatino
Stroke as a cause of long-term disability is a growing public health burden. Therefore, focusing on prevention is important. The most prominent aim of this strategy is to treat modifiable risk factors, such as arterial hypertension, the leading modifiable contributor to stroke. Thus, efforts to adequately reduce blood pressure (BP) among hypertensives are mandatory. In this respect, although safety and benefits of BP control related to long-term outcome have been largely demonstrated, there are open questions that remain to be addressed, such as optimal timing to initiate BP reduction and BP goals to be targeted...
November 16, 2017: Current Vascular Pharmacology
Jose Luis Guerrero Orriach, A Ramirez Fernandez, J J Escalona Belmonte, M Rubio Navarro, M Rubio Navarro, J Cruz Manas
we try to answer four questions in this review, what type of patients need this drug; what is the best time to start with it, the best way that we could give it and finally the reasons for use it.
November 16, 2017: Current Vascular Pharmacology
Lukasz J Krzych, Anna J Szczepanska
BACKGROUND: Volatile anaesthetics (VA) are commonly used worldwide for induction and/or maintenance of general anaesthesia. They act in the central nervous system to reduce sensation and motor response during surgical and invasive diagnostic procedures. VAs also have some non-anaesthetic properties in the brain when administrated to patients at the extremes of age. Their biological impact on other organs should be taken into account during administration of anaesthesia. OBJECTIVE: In this review we summarize the recent knowledge on the non-anaesthetic effects of inhaled halogenic ethers on cells and tissues...
October 13, 2017: Current Vascular Pharmacology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"